TrialScience translational medicine2022

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.

Pavlos Msaouel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.